Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07198724 |
| Title | ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer (ERADICATE) |
| Acronym | ERADICATE |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Sarah Sammons, MD |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA |